Cancer Drugs Market Size, Trends & Forecast (2025–2031) | Growth at 12.6% CAGR
Cancer Drugs Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Chemotherapy, Targeted Therapy, Radiation Therapy, Hormone Therapy, and Other Therapy Types), By Indications (Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Ducts Cancer, Thyroid Cancer, and Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Stores), and Geography
- Report Date : Aug 2025
- Report Code : TIPRE00040984
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 277
The cancer drugs market size is projected to reach US$ 516.15 billion by 2031 from US$ 225.96 billion in 2024. The market is expected to register a CAGR of 12.60% from 2025 to 2031.
Cancer Drugs Market Analysis
The growing burden of breast and lung cancer and surging investments in oncology research are propelling the use of cancer drugs. Cancer drugs are medications used to treat cancer. They work through various mechanisms, including targeting cancer cells directly, preventing their growth and spread, or stimulating the body's immune system to attack cancer cells. These drugs are categorized into different types based on their mechanism of action and can be used alone or in combination.
Additionally, the increased government and private organizations support presents a significant opportunity for the cancer drugs market and is a key factor contributing to market growth.
Cancer Drugs Market Overview
North America is projected to dominate the cancer drugs market with the largest share, and Asia Pacific is expected to register a significant CAGR during the forecast period. The cancer drugs market in Asia Pacific is experiencing rapid growth due to several key factors. This region includes major countries such as China, Japan, India, South Korea, Australia, and the broader Asia Pacific area, each contributing to this market expansion. North America, particularly the US, records a high prevalence of cancer. Also, a large elderly population is at a greater risk of the disease. The rising number of cancer cases fuels the demand for advanced therapeutics and treatment options.
Furthermore, the rising number of cancer cases fuels the demand for advanced therapeutics and treatment options. Technological advancements and access to cost-effective manufacturing in the region allow companies to produce efficient drugs at competitive prices, further enhancing their market presence.
Government bodies are making cancer treatments accessible by implementing people-friendly reimbursement policies and other healthcare initiatives to provide satisfactory cost coverage for cancer therapeutics.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Cancer Drugs Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Cancer Drugs Market Drivers and Opportunities
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Cancer Drugs Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Drivers:
Growing Burden of Breast and Lung Cancer:
The growing burden of breast and lung cancer is a significant driver of the cancer drugs market. Additionally, the rising awareness of cancer among the population is expected to contribute positively to the development of this market.Surging Investments in Oncology Research:
Research and development activities have become the foundation for discovering innovative drugs and therapeutic strategies with the rising demand for more effective and targeted cancer therapies.Advances in Precision Medicine:
Many novel cancer drugs, especially biologics and cell therapies, carry high price tags. This increases affordability concerns, strains public health budgets, and creates access disparities. Payers and governments increasingly assess value-based pricing, leading to debates on pricing transparency, reimbursement models, and global cost-containment policies.
Market Opportunities:
Increased Support from Government and Private Organizations:
Several governments and private organizations have increased funding for research and development in cancer treatment, resulting in the development of innovative drugs and therapies.
Technological Advancements
Technological advancements and access to cost-effective manufacturing in the region allow companies to produce innovative drugs at competitive prices, further enhancing their market presence.
Expansion in Emerging Economies:
Several countries in Asia Pacific, Latin America, and Africa offer growth opportunities in the cancer drugs market due to the increasing number cancer cases and awareness about cancer.Rising Medical Tourism:
Increasing medical tourism in developing countries such as China, India, Indonesia, Brazil, and Mexico, offer affordable advanced care and treatments, which are 30–80% less than in the US and European countries.
Cancer Drugs Market Report Segmentation Analysis
The cancer drugs market is divided into different segments to give a clearer view of how it works, its growth potential, and the latest trends. Below is the standard segmentation approach used in most industry reports:
By Therapy Types:
Chemotherapy:
Chemotherapy drugs primarily target rapidly dividing cells, and can also affect healthy, fast-growing cells such as hair follicles, the digestive system, and bone marrow.Targeted Therapy:
Targeted drugs inhibit cancer cells' growth by destroying or slowing down their growth. Targeted therapy is used in combination with traditional chemotherapy.Immunotherapy:
Immunotherapy leverages an individual's immune system to recognize and destroy cancer cells effectively. It typically targets specific proteins in the body's immune system to enhance the immune response.Hormonal Therapy:
Hormonal therapy (hormone therapy, hormone-blocking therapy, or endocrine therapy) is a type of cancer treatment designed to slow or stop the growth of cancer cells that depend on hormones for their development.Other Therapy Types:
Gene therapy, cancer vaccines, and epigenetic therapy are a few of the most innovative and promising approaches in cancer treatment.
By Indications:
Blood Cancer:
The blood cancer drugs market has grown significantly due to advancements in targeted therapies, immunotherapies, and personalized medicine.Lung Cancer:
The lung cancer drugs market continues to evolve with rapid advancements in treatment modalities. Targeted therapies, immunotherapies, and precision medicine are reshaping the landscape for lung cancer treatment.Breast Cancer:
The breast cancer drugs market is characterized by a diverse range of treatment modalities that are available and in development; these promising therapy options include targeted therapies, hormone therapies, immunotherapies, and precision medicine, which are transforming the market dynamics and offering hope for patients with various stages and subtypes of breast cancer.Colorectal Cancer:
The colorectal cancer drugs market is driven by ongoing research and development for innovative therapies to improve patient outcomes..Prostate Cancer:
Prostate cancer ranks second among the most prevalent cancer types affecting men globally, after lung cancer, in terms of incidence and mortality.Stomach Cancer:
Stomach cancer, also known as gastric cancer, ranks as the fifth most common cancer in terms of incidence in the world. Recent scientific and clinical developments are transforming the landscape of gastric cancer diagnosis and treatment.Cervical Cancer:
Cervical cancer is one of the most common cancer types affecting women worldwide. While cervical cancer rates have decreased in many developed countries due to widespread, proactive HPV vaccination programs and cervical screening, the disease continues to be a significant health challenge, particularly in low- and middle-income countries.Liver and Intrahepatic Bile Ducts Cancer:
The liver and intrahepatic bile ducts segment of the cancer drugs market is critical because liver and bile duct cancers are among the most aggressive and challenging to treat, as they are often diagnosed at advanced stages.Thyroid Cancer:
Thyroid cancer, though relatively rare compared to other cancers, is the most common endocrine malignancy and includes subtypes such as papillary, follicular, medullary, and anaplastic thyroid cancers.Other Indications:
The other indications mainly include corpus uteri cancer, oral cavity cancer, melanoma of skin cancer, ovarian cancer, and larynx cancer.
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
The cancer drugs market in North America is expected to hold a significant share of the market. Increasing cancer prevalence and business expansion strategies by the market players are factors likely to drive the market.
Cancer Drugs Market Report ScopeCancer drugs market Share Analysis by Geography
Asia Pacific is expected to grow the fastest in the next few years. Emerging markets in Latin America, the Middle East, and Africa also have many untapped opportunities for cancer drugs providers to expand.
The cancer drugs market grows differently in each region. This is because of factors like increasing prevalence of cancer cases, surging investments in oncology research, and increasing adoption of innovative oncology drugs. Below is a summary of market share and trends by region:
1. North America
Market Share:
Holds a significant portion of the global marketKey Drivers:
- Growing Burden of Breast and Lung Cancer.
- Surging Investments in Oncology Research
- Growth in Personalized Medicine
Trends:
Adoption of organic and inorganic strategies by cancer drugs manufacturers.
2. Europe
Market Share:
Substantial share due to early adoption of digital commerceKey Drivers:
- Rising prevalence of cancer
- Strict government regulation for cancer drugs
Trends:
Technological advancements in cancer drugs
3. Asia Pacific
Market Share:
Fastest-growing region with rising market share every yearKey Drivers:
- Rapid improvements in healthcare infrastructure, supported by increasing government investments in public health.
- Growing awareness of cancer drugs among the public and various institutions.
Trends:
Rise in medical tourism
4. South and Central America
Market Share:
Growing market with steady progressKey Drivers:
- Growing number of cancer cases
- Increasing import of pharmaceutical drugs
Trends:
Rise in medical tourism
5. Middle East and Africa
Market Share:
Although small, but growing quicklyKey Drivers:
- Expanding Healthcare infrastructure
- Rising awareness about cancer drugs in healthcare settings
Trends:
Government initiatives for cancer drugs awareness.
Cancer Drugs Market Players Density: Understanding Its Impact on Business Dynamics
High Market Density and Competition
Competition is strong due to the presence of established players such as Roche, Pfizer, Novartis, Merck, Bristol-Myers Squibb, AbbVie, Lilly, AstraZeneca. Regional and niche providers like Novugen Pharma (Malaysia) and Kalbe Farma (Asia Pacific) are also adding to the competitive landscape across different regions.
This high level of competition urges companies to stand out by offering:
- Advanced Product
- Competitive Pricing Models
- Compliance with Regulatory Guidelines
Opportunities and Strategic Moves
- Focusing on more effective and targeted cancer therapies. A surge in research and development investments is due to increasing cancer rates and the need for advanced therapies.
- Companies are moving towards next-generation oncology therapeutics and precision approaches to address regulatory and consumer concerns about cancer therapies
- Focusing on direct-to-consumer channels and enhance the use of e-commerce platforms to reach a wider range of customer segments.
Major Companies operating in the Cancer Drugs Market are:
- Bristol-Myers Squibb Co.
- AbbVie Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- AstraZeneca Plc
- Merck KGaA
- Novartis AG
- Astellas Pharma Inc.
- Eli Lilly and Co.
Disclaimer: The companies listed above are not ranked in any particular order.
Other companies analysed during the course of research:
- Takeda Pharmaceutical Company
- Incyte
- Gilead Science, Inc.
- Daiichi Sankyo Co. Ltd
- Lupin Pharmaceuticals
- Ipsen
- Boehringer Ingelheim
- Glenmark Pharmaceuticals
- Gilead Sciences
- Odon Lifescience
- Cytogen Pharmaceuticals India Private Limited
- Bluebird Bio
- Biocon Limited
- BeiGene
- Amgen, Inc.
- Ascendis Pharma
- Sun Pharmaceutical Industries
- Clovis Oncology
- Cipla Limited
- Blueprint Medicines
Cancer Drugs Market News and Recent Developments
Glenmark to Launch DCGI-Approved Cancer Drug in India
Glenmark Pharmaceuticals is set to introduce zanubrutinib, a cancer treatment drug, in India. This follows approval from the Drugs Controller General of India. The drug, branded as Brukinsa, treats five B-cell malignancies.
Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer.
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1, or PTEN).
Cancer Drugs Market Report Coverage and Deliverables
The "Cancer drugs market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
- Cancer drugs market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Cancer drugs market trends, as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Cancer drugs market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the cancer drugs market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The growing burden of breast and lung cancer, and surging investments in oncology research, are among the noteworthy factors contributing to the market growth.
North America dominated the market in 2024.
The cancer drugs market is estimated to reach US$ 516.15 billion by 2031.
The cancer drugs market is estimated to register a CAGR of 12.6% during the forecast period.
Bristol-Myers Squibb Co.; AbbVie Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca Plc; Merck KGaA; Novartis AG; Astellas Pharma Inc.; and Eli Lilly and Co. are among the key players operating in the cancer drugs market.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
3.3 Assumptions and Limitations
4. Cancer Drugs Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in Value Chain
5. Cancer Drugs Market – Key Market Dynamics
5.1 Cancer Drugs Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Growing Burden of Breast and Lung Cancer
5.2.2 Surging Investments in Oncology Research
5.3 Market Restraints
5.3.1 High Cost of Treatment
5.4 Market Opportunities
5.4.1 Increased Support from Government and Private Organizations
5.5 Future Trends
5.5.1 Preference for Personalized Medicine
5.6 Impact of Drivers and Restraints:
6. Cancer Drugs Market – Global Market Analysis
6.1 Cancer Drugs Market Revenue (US$ Million), 2021–2031
6.2 Cancer Drugs Market Forecast Analysis
7. Cancer Drugs Market Analysis – by Therapy Types
7.1 Chemotherapy
7.1.1 Overview
7.1.2 Chemotherapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.2 Targeted Therapy
7.2.1 Overview
7.2.2 Targeted Therapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.4 Hormonal Therapy
7.4.1 Overview
7.4.2 Hormonal Therapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.5 Other Therapy Types
7.5.1 Overview
7.5.2 Other Therapy Types: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8. Cancer Drugs Market Analysis – by Indications
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.2 Lung Cancer
8.2.1 Overview
8.2.2 Lung Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.4 Colorectal Cancer
8.4.1 Overview
8.4.2 Colorectal Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.5 Prostate Cancer
8.5.1 Overview
8.5.2 Prostate Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.6 Stomach Cancer
8.6.1 Overview
8.6.2 Stomach Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.7 Cervical Cancer
8.7.1 Overview
8.7.2 Cervical Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.8 Liver and Intrahepatic Bile Ducts Cancer
8.8.1 Overview
8.8.2 Liver and Intrahepatic Bile Ducts Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.9 Thyroid Cancer
8.9.1 Overview
8.9.2 Thyroid Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.10 Other Indications
8.10.1 Overview
8.10.2 Other Indications: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9. Cancer Drugs Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Overview
9.1.2 Hospital Pharmacies: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.2 Retail Pharmacies
9.2.1 Overview
9.2.2 Retail Pharmacies: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.3 Online Stores
9.3.1 Overview
9.3.2 Online Stores: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10. Cancer Drugs Market – Geographical Analysis
10.1 Overview
10.2 North America
10.2.1 North America Cancer Drugs Market Overview
10.2.2 North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3 North America: Cancer Drugs Market Share – by Therapy Types
10.2.3.1 North America: Cancer Drugs Market– Revenue and Forecast Analysis – by Therapy Types
10.2.4 North America: Cancer Drugs Market Share – by Indications
10.2.4.1 North America: Cancer Drugs Market– Revenue and Forecast Analysis – by Indications
10.2.5 North America: Cancer Drugs Market Share – by Distribution Channel
10.2.5.1 North America: Cancer Drugs Market– Revenue and Forecast Analysis – by Distribution Channel
10.2.6 North America: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.2.6.1 North America: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.2.6.2 United States: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.6.2.1 United States: Cancer Drugs Market Share – by Therapy Types
10.2.6.2.2 United States: Cancer Drugs Market Share – by Indications
10.2.6.2.3 United States: Cancer Drugs Market Share – by Distribution Channel
10.2.6.3 Canada: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.6.3.1 Canada: Cancer Drugs Market Share – by Therapy Types
10.2.6.3.2 Canada: Cancer Drugs Market Share – by Indications
10.2.6.3.3 Canada: Cancer Drugs Market Share – by Distribution Channel
10.2.6.4 Mexico: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.6.4.1 Mexico: Cancer Drugs Market Share – by Therapy Types
10.2.6.4.2 Mexico: Cancer Drugs Market Share – by Indications
10.2.6.4.3 Mexico: Cancer Drugs Market Share – by Distribution Channel
10.3 Europe
10.3.1 Europe Cancer Drugs Market Overview
10.3.2 Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3 Europe: Cancer Drugs Market Share – by Therapy Types
10.3.3.1 Europe: Cancer Drugs Market– Revenue and Forecast Analysis – by Therapy Types
10.3.4 Europe: Cancer Drugs Market Share – by Indications
10.3.4.1 Europe: Cancer Drugs Market– Revenue and Forecast Analysis – by Indications
10.3.5 Europe: Cancer Drugs Market Share – by Distribution Channel
10.3.5.1 Europe: Cancer Drugs Market– Revenue and Forecast Analysis – by Distribution Channel
10.3.6 Europe: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.3.6.1 Europe: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.3.6.2 Germany: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.2.1 Germany: Cancer Drugs Market Share – by Therapy Types
10.3.6.2.2 Germany: Cancer Drugs Market Share – by Indications
10.3.6.2.3 Germany: Cancer Drugs Market Share – by Distribution Channel
10.3.6.3 United Kingdom: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.3.1 United Kingdom: Cancer Drugs Market Share – by Therapy Types
10.3.6.3.2 United Kingdom: Cancer Drugs Market Share – by Indications
10.3.6.3.3 United Kingdom: Cancer Drugs Market Share – by Distribution Channel
10.3.6.4 France: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.4.1 France: Cancer Drugs Market Share – by Therapy Types
10.3.6.4.2 France: Cancer Drugs Market Share – by Indications
10.3.6.4.3 France: Cancer Drugs Market Share – by Distribution Channel
10.3.6.5 Italy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.5.1 Italy: Cancer Drugs Market Share – by Therapy Types
10.3.6.5.2 Italy: Cancer Drugs Market Share – by Indications
10.3.6.5.3 Italy: Cancer Drugs Market Share – by Distribution Channel
10.3.6.6 Spain: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.6.1 Spain: Cancer Drugs Market Share – by Therapy Types
10.3.6.6.2 Spain: Cancer Drugs Market Share – by Indications
10.3.6.6.3 Spain: Cancer Drugs Market Share – by Distribution Channel
10.3.6.7 Rest of Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.7.1 Rest of Europe: Cancer Drugs Market Share – by Therapy Types
10.3.6.7.2 Rest of Europe: Cancer Drugs Market Share – by Indications
10.3.6.7.3 Rest of Europe: Cancer Drugs Market Share – by Distribution Channel
10.4 Asia Pacific
10.4.1 Asia Pacific Cancer Drugs Market Overview
10.4.2 Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.3 Asia Pacific: Cancer Drugs Market Share – by Therapy Types
10.4.3.1 Asia Pacific: Cancer Drugs Market– Revenue and Forecast Analysis – by Therapy Types
10.4.4 Asia Pacific: Cancer Drugs Market Share – by Indications
10.4.4.1 Asia Pacific: Cancer Drugs Market– Revenue and Forecast Analysis – by Indications
10.4.5 Asia Pacific: Cancer Drugs Market Share – by Distribution Channel
10.4.5.1 Asia Pacific: Cancer Drugs Market– Revenue and Forecast Analysis – by Distribution Channel
10.4.6 Asia Pacific: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.4.6.1 Asia Pacific: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.4.6.2 China: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.2.1 China: Cancer Drugs Market Share – by Therapy Types
10.4.6.2.2 China: Cancer Drugs Market Share – by Indications
10.4.6.2.3 China: Cancer Drugs Market Share – by Distribution Channel
10.4.6.3 Japan: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.3.1 Japan: Cancer Drugs Market Share – by Therapy Types
10.4.6.3.2 Japan: Cancer Drugs Market Share – by Indications
10.4.6.3.3 Japan: Cancer Drugs Market Share – by Distribution Channel
10.4.6.4 India: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.4.1 India: Cancer Drugs Market Share – by Therapy Types
10.4.6.4.2 India: Cancer Drugs Market Share – by Indications
10.4.6.4.3 India: Cancer Drugs Market Share – by Distribution Channel
10.4.6.5 South Korea: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.5.1 South Korea: Cancer Drugs Market Share – by Therapy Types
10.4.6.5.2 South Korea: Cancer Drugs Market Share – by Indications
10.4.6.5.3 South Korea: Cancer Drugs Market Share – by Distribution Channel
10.4.6.6 Australia: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.6.1 Australia: Cancer Drugs Market Share – by Therapy Types
10.4.6.6.2 Australia: Cancer Drugs Market Share – by Indications
10.4.6.6.3 Australia: Cancer Drugs Market Share – by Distribution Channel
10.4.6.7 Rest of APAC: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.7.1 Rest of APAC: Cancer Drugs Market Share – by Therapy Types
10.4.6.7.2 Rest of APAC: Cancer Drugs Market Share – by Indications
10.4.6.7.3 Rest of APAC: Cancer Drugs Market Share – by Distribution Channel
10.5 Middle East and Africa
10.5.1 Middle East and Africa Cancer Drugs Market Overview
10.5.2 Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.3 Middle East and Africa: Cancer Drugs Market Share – by Therapy Types
10.5.3.1 Middle East and Africa: Cancer Drugs Market– Revenue and Forecast Analysis – by Therapy Types
10.5.4 Middle East and Africa: Cancer Drugs Market Share – by Indications
10.5.4.1 Middle East and Africa: Cancer Drugs Market– Revenue and Forecast Analysis – by Indications
10.5.5 Middle East and Africa: Cancer Drugs Market Share – by Distribution Channel
10.5.5.1 Middle East and Africa: Cancer Drugs Market– Revenue and Forecast Analysis – by Distribution Channel
10.5.6 Middle East and Africa: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.5.6.1 Middle East and Africa: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.5.6.2 Turkey: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.6.2.1 Turkey: Cancer Drugs Market Share – by Therapy Types
10.5.6.2.2 Turkey: Cancer Drugs Market Share – by Indications
10.5.6.2.3 Turkey: Cancer Drugs Market Share – by Distribution Channel
10.5.6.3 GCC Countries: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.6.3.1 GCC Countries: Cancer Drugs Market Share – by Therapy Types
10.5.6.3.2 GCC Countries: Cancer Drugs Market Share – by Indications
10.5.6.3.3 GCC Countries: Cancer Drugs Market Share – by Distribution Channel
10.5.6.4 South Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.6.4.1 South Africa: Cancer Drugs Market Share – by Therapy Types
10.5.6.4.2 South Africa: Cancer Drugs Market Share – by Indications
10.5.6.4.3 South Africa: Cancer Drugs Market Share – by Distribution Channel
10.5.6.5 Rest of Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.6.5.1 Rest of Middle East and Africa: Cancer Drugs Market Share – by Therapy Types
10.5.6.5.2 Rest of Middle East and Africa: Cancer Drugs Market Share – by Indications
10.5.6.5.3 Rest of Middle East and Africa: Cancer Drugs Market Share – by Distribution Channel
10.6 South and Central America
10.6.1 South and Central America Cancer Drugs Market Overview
10.6.2 South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.6.3 South and Central America: Cancer Drugs Market Share – by Therapy Types
10.6.3.1 South and Central America: Cancer Drugs Market– Revenue and Forecast Analysis – by Therapy Types
10.6.4 South and Central America: Cancer Drugs Market Share – by Indications
10.6.4.1 South and Central America: Cancer Drugs Market– Revenue and Forecast Analysis – by Indications
10.6.5 South and Central America: Cancer Drugs Market Share – by Distribution Channel
10.6.5.1 South and Central America: Cancer Drugs Market– Revenue and Forecast Analysis – by Distribution Channel
10.6.6 South and Central America: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.6.6.1 South and Central America: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.6.6.2 Brazil: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.6.6.2.1 Brazil: Cancer Drugs Market Share – by Therapy Types
10.6.6.2.2 Brazil: Cancer Drugs Market Share – by Indications
10.6.6.2.3 Brazil: Cancer Drugs Market Share – by Distribution Channel
10.6.6.3 Argentina: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.6.6.3.1 Argentina: Cancer Drugs Market Share – by Therapy Types
10.6.6.3.2 Argentina: Cancer Drugs Market Share – by Indications
10.6.6.3.3 Argentina: Cancer Drugs Market Share – by Distribution Channel
10.6.6.4 Rest of South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.6.6.4.1 Rest of South and Central America: Cancer Drugs Market Share – by Therapy Types
10.6.6.4.2 Rest of South and Central America: Cancer Drugs Market Share – by Indications
10.6.6.4.3 Rest of South and Central America: Cancer Drugs Market Share – by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Bristol-Myers Squibb Co
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 AbbVie Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Astellas Pharma Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Eli Lilly and Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Novartis AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Merck KGaA
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 AstraZeneca
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Pfizer Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 F. Hoffmann-La Roche Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Johnson & Johnson
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About Us
14.2 List of Abbreviations
List of Tables
Table 1. Cancer Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Table 4. Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 5. Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 6. Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 7. North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 8. North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 9. North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 10. North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 11. United States: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 12. United States: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 13. United States: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 14. Canada: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 15. Canada: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 16. Canada: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 17. Mexico: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 18. Mexico: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 19. Mexico: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 20. Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 21. Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 22. Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 23. Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 24. Germany: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 25. Germany: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 26. Germany: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 27. United Kingdom: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 28. United Kingdom: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 29. United Kingdom: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 30. France: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 31. France: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 32. France: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 33. Italy: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 34. Italy: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 35. Italy: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 36. Spain: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 37. Spain: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 38. Spain: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 39. Rest of Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 40. Rest of Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 41. Rest of Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 42. Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 43. Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 44. Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 45. Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 46. China: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 47. China: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 48. China: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 49. Japan: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 50. Japan: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 51. Japan: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 52. India: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 53. India: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 54. India: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 55. South Korea: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 56. South Korea: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 57. South Korea: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 58. Australia: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 59. Australia: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 60. Australia: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 61. Rest of APAC: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 62. Rest of APAC: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 63. Rest of APAC: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 64. Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 65. Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 66. Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 67. Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 68. Turkey: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 69. Turkey: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 70. Turkey: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 71. GCC Countries: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 72. GCC Countries: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 73. GCC Countries: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 74. South Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 75. South Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 76. South Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 77. Rest of Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 78. Rest of Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 79. Rest of Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 80. South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 81. South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 82. South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 83. South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 84. Brazil: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 85. Brazil: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 86. Brazil: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 87. Argentina: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 88. Argentina: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 89. Argentina: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 90. Rest of South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 91. Rest of South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 92. Rest of South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 93. List of Abbreviations
List of Figures
Figure 1. Cancer Drugs Market Segmentation – Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Cancer Drugs Market Revenue (US$ Million), 2021–2031
Figure 5. Cancer Drugs Market Share (%) – by Therapy Types (2024 and 2031)
Figure 6. Chemotherapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 7. Targeted Therapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 8. Immunotherapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 9. Hormonal Therapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 10. Other Therapy Types: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 11. Cancer Drugs Market Share (%) – by Indications (2024 and 2031)
Figure 12. Blood Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 13. Lung Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 14. Breast Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 15. Colorectal Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 16. Prostate Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 17. Stomach Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 18. Cervical Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 19. Liver and Intrahepatic Bile Ducts Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 20. Thyroid Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 21. Other Indications: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 22. Cancer Drugs Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 23. Hospital Pharmacies: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 24. Retail Pharmacies: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 25. Online Stores: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 26. Cancer Drugs Market Regional Share, 2024 and 2031 (%)
Figure 27. North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Figure 28. North America: Cancer Drugs Market Share – by Therapy Types (2024 and 2031)
Figure 29. North America: Cancer Drugs Market Share – by Indications (2024 and 2031)
Figure 30. North America: Cancer Drugs Market Share – by Distribution Channel (2024 and 2031)
Figure 31. North America: Cancer Drugs Market Share – Key Countries, 2024 and 2031 (%)
Figure 32. United States: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 33. Canada: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 34. Mexico: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 35. Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Figure 36. Europe: Cancer Drugs Market Share – by Therapy Types (2024 and 2031)
Figure 37. Europe: Cancer Drugs Market Share – by Indications (2024 and 2031)
Figure 38. Europe: Cancer Drugs Market Share – by Distribution Channel (2024 and 2031)
Figure 39. Europe: Cancer Drugs Market Share – Key Countries, 2024 and 2031 (%)
Figure 40. Germany: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 41. United Kingdom: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 42. France: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 43. Italy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 44. Spain: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 45. Rest of Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 46. Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Figure 47. Asia Pacific: Cancer Drugs Market Share – by Therapy Types (2024 and 2031)
Figure 48. Asia Pacific: Cancer Drugs Market Share – by Indications (2024 and 2031)
Figure 49. Asia Pacific: Cancer Drugs Market Share – by Distribution Channel (2024 and 2031)
Figure 50. Asia Pacific: Cancer Drugs Market Share – Key Countries, 2024 and 2031 (%)
Figure 51. China: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 52. Japan: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 53. India: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 54. South Korea: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 55. Australia: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 56. Rest of APAC: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 57. Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Figure 58. Middle East and Africa: Cancer Drugs Market Share – by Therapy Types (2024 and 2031)
Figure 59. Middle East and Africa: Cancer Drugs Market Share – by Indications (2024 and 2031)
Figure 60. Middle East and Africa: Cancer Drugs Market Share – by Distribution Channel (2024 and 2031)
Figure 61. Middle East and Africa: Cancer Drugs Market Share – Key Countries, 2024 and 2031 (%)
Figure 62. Turkey: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 63. GCC Countries: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 64. South Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 65. Rest of Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 66. South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Figure 67. South and Central America: Cancer Drugs Market Share – by Therapy Types (2024 and 2031)
Figure 68. South and Central America: Cancer Drugs Market Share – by Indications (2024 and 2031)
Figure 69. South and Central America: Cancer Drugs Market Share – by Distribution Channel (2024 and 2031)
Figure 70. South and Central America: Cancer Drugs Market Share – Key Countries, 2024 and 2031 (%)
Figure 71. Brazil: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 72. Argentina: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 73. Rest of South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 74. Heat Map Analysis by Key Players
Figure 75. Company Positioning and Concentration
The List of Companies - Cancer Drugs Market
- Bristol-Myers Squibb Co.
- AbbVie Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- AstraZeneca Plc
- Merck KGaA
- Novartis AG
- Astellas Pharma Inc.
- Eli Lilly and Co.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For